Table 1.

Baseline characteristics and clinical outcomes of all patients taking PPIs at baseline that were continued for >2 days compared with patients not prescribed PPIs during hospitalisation or at discharge.

	PPI at baseline	Non-PPI at baseline	P value
Baseline clinical characteristics
Number	384	295
Mean age (yrs, SD)	53.7 (10.6)	53.5 (10.6)	0.80
Male	275 (71.6%)	208 (70.5%)	0.86
Female	109 (28.4%)	87 (29.5%)	0.86
Alcohol	356 (92.7%)	257 (87.1%)	0.03∗
Alcoholic Hepatitis	96 (25.2%)	70 (23.7%)	0.75
Albumin treatment	194 (50.5%)	150 (50.8%)	0.93
NSBB use	92 (24%)	37 (12.5%)	0.0002∗
Suspected Variceal Bleed	86 (22.6%)	14 (4.75%)	1.64194E-10∗
Ascites	241 (63.1%)	208 (70.5%)	0.037
Use of antibiotics	217 (56.5%)	137 (46.4%)	0.01∗
Use of Prednisolone ≥30 mg od	53 (13.8%)	28 (9.5%)	0.09
MELD Score - median (95% CI)	18.94 (17.9–20.1)	19.58 (18.6–20.6)	0.10
Serum Albumin g/L - median (95% CI)	24 (23–24)	24 (23–24)	0.81
Creatinine mmol/L - median (95% CI)	69 (66–73)	66 (63–69)	0.09
WCC x109/L - median (95% CI)	7.2 (6.8–7.7)	8.1 (7.5–8.8)	0.003∗
CRP mg/L - median (95% CI)	24 (21–28)	23 (21–29)	0.57
Bilirubin mg/L - median (95% CI)	84.5 (72–96)	109 (94–127)	0.002∗
Primary Clinical Outcomes
Diagnosis of infection at randomisation	104 (27.1%)	80 (27.1%)	0.97
Incidence of new infection (days 3–15)	70 (18.2%)	54 (18.3%)	0.98
New infection reported as SBP	5 (1.3%)	5 (1.7%)	0.67
HE at randomisation (all grades)	83 (21.8%)	46 (15.6%)	0.054
Incidence of new grade III/IV HE (days 3–15)	33 (8.6%)	11 (3.7%)	0.011∗
Incidence of new grade I/II HE (days 3–15)	31 (8.1%)	22 (7.5%)	0.77
Secondary Clinical Outcomes
Incidence of renal dysfunction (days 3–15)	51 (13.3%)	32 (10.9%)	0.34
Incidence of death during hospitalisation (days 3–15)	30 (7.8%)	24 (8.5%)	0.88
28-day mortality	60 (15.2%)	40 (13.6%)	0.45
90-day mortality	90 (22.8%)	67 (22.7%)	0.82
180-day mortality	120 (30.5%)	95 (32.2%)	0.79

∗P values < 0.05.